Work

635P Association of ceramide metabolism with resistance to androgen receptor signalling inhibitors in metastatic prostate cancer

Year: 2021

Type: article

Source: Annals of Oncology

DOI: 10.1016/j.annonc.2021.08.1148

Authors: H-M. Lin, B. Mak, K. Huynh, E.M. Kwan, H. Fettke, B. Tran, I.D. Davis, K.L. Mahon, M.R. Stockler, K. Briscoe, G.M. Marx, P. Du, J. Yu, S. Jia, A.M. Joshua, A.A. Azad, L.M. Butler, P.J. Meikle, L.G. Horvath

Institutions: Garvan Institute of Medical Research, Baker Heart and Diabetes Institute, Monash Health, Peter MacCallum Cancer Centre, Eastern Health, Monash University, Chris O’Brien Lifehouse, Sydney Adventist Hospital, St Vincent's Hospital Sydney, Freemasons Foundation Centre for Men's Health, The University of Adelaide

Language: English

Topic: Prostate Cancer Treatment and Research

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

Funders: Amgen, Bristol-Myers Squibb, Pfizer, AstraZeneca, Sanofi, Astellas Pharma, Ipsen, Australian and New Zealand Urogenital and Prostate Cancer Trials Group

OpenAlex ID: W3202822926

FWCI:

Cites:

Cited by:

Related to: 10